CIDM vs. BTX, ALFIW, and NLOK
Should you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.
Brooklyn ImmunoTherapeutics (NYSE:BTX) and Cinedigm (NASDAQ:CIDM) are both small-cap information companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
26.0% of Brooklyn ImmunoTherapeutics shares are held by institutional investors. Comparatively, 8.0% of Cinedigm shares are held by institutional investors. 20.5% of Brooklyn ImmunoTherapeutics shares are held by company insiders. Comparatively, 16.4% of Cinedigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Brooklyn ImmunoTherapeutics has a beta of 4.61, meaning that its share price is 361% more volatile than the S&P 500. Comparatively, Cinedigm has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.
Brooklyn ImmunoTherapeutics and Cinedigm both received 0 outperform votes by MarketBeat users.
Brooklyn ImmunoTherapeutics has higher earnings, but lower revenue than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cinedigm had 1 more articles in the media than Brooklyn ImmunoTherapeutics. MarketBeat recorded 1 mentions for Cinedigm and 0 mentions for Brooklyn ImmunoTherapeutics. Brooklyn ImmunoTherapeutics' average media sentiment score of 0.59 beat Cinedigm's score of 0.00 indicating that Cinedigm is being referred to more favorably in the news media.
Summary
Brooklyn ImmunoTherapeutics and Cinedigm tied by winning 4 of the 8 factors compared between the two stocks.
Get Cinedigm News Delivered to You Automatically
Sign up to receive the latest news and ratings for CIDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CIDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cinedigm Competitors List
Related Companies and Tools